Navigation Links
Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
Date:4/14/2009

COSTA MESA, Calif., April 14 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced it has reached a development and commercial supply agreement with Hospira Inc.'s One 2 One(R) Global Pharmaceutical Services business unit to manufacture clinical-grade Oxycyte(R). Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier. Oxycyte will be manufactured at Hospira's Clayton, North Carolina, facility which specializes in emulsion technology.

Hospira will formulate, fill, finish and label Oxycyte to meet clinical good manufacturing practice (GMP) standards required for use of drugs in human patients. The amount of Oxycyte supplied by Hospira will be sufficient to meet any expected demand for the foreseeable future.

"This agreement connects us to a first-tier contract manufacturer and superbly reliable supplier who will provide us with all the Oxycyte we need to grow the company. As I've previously stated, our strategy is to license marketing rights for individual indications, yet always control the supply of our compound and be able to profit from sales of Oxycyte to licensees," said Chris J. Stern, company chairman and CEO.

The companies are not disclosing the financial terms of the supply agreement.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets includin
'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
2. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
3. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
4. Oxygen Biotherapeutics, Inc. Expands Board of Directors
5. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
6. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
7. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
8. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
9. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
10. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
11. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015  UBM Medica US announces ... leading online community to help oncologists and other ... information available regarding the use of targeted therapies ... March is National Kidney Cancer ... effective adjuvant treatment options for renal cell carcinoma ...
(Date:3/5/2015)... e2b teknologies , a premier ... Northeast Ohio, today announced a leading independent multi-specialty physician ... upgrade to the latest version of Sage 100 ... of its kind in the region, the organization has ... so efficiency and data accessibility are paramount to their ...
(Date:3/4/2015)... Nev. , March 4, 2015 PDL BioPharma, Inc. ... adjusted conversion rate for the: , 3.75% Convertible ... 174.8506 shares of common stock per $1,000 principal amount or ... The conversion rate for the note is adjusted in connection ... on March 12, 2015, to all stockholders who own shares of ...
(Date:3/4/2015)... N.Y. , March 4, 2015  Brooklyn residents ... their acute and chronic pain and injuries. Nunzio ... announce the grand opening of his NJS Physical Medicine ... on Thursday, March 5, 2015. Health Plus ... facility, which is located at 1178 Flatbush Avenue. This ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... June 10 BioSpecifics,Technologies Corp. (OTC BB BSTC.OB-News) ... unregistered shares of its common stock priced at ... $1,500,000. The shares,were purchased by certain private investors ... a company managed PIPE transaction at a premium ...
... June 10 DURECT Corporation,(Nasdaq: DRRX ) ... for,Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to the ... drug, is a long,acting oral formulation of oxycodone ... DURECT,s ORADUR technology, Remoxy is designed to resist,common ...
... pipeline of biologics ... disease and cancer, CAMBRIDGE, Mass., June 10 Merrimack ... of,novel treatments for autoimmune disease and cancer, today announced that ... financing., Existing and new investors participated in the financing ...
Cached Biology Technology:New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... 27, 2007 New protocol and software developments are helping ... making it easier for growers to use previously ineffectual ... Historically, gaps between researchers and producers, as well ... decisions, have all contributed to data languishing on hard ...
... new and extraordinary $22 million gift to the University of ... institute one with a mission of supporting fundamental research ... of a broad range of human diseases. The A. ... Medical School, is named for the retail pioneer whose funding ...
... ANGELES (September 25, 2007) Stem cell therapy for ... the media will be the focus of the keynote ... the Treatment of Cardiovascular Disease conference. Conducted by Cedars-Sinai ... 4 and 5, the conference is co-sponsored by the ...
Cached Biology News:Emphasizing the 'precision' in precision agriculture 2$22 million gift from Alfred Taubman launches new biomedical research institute 2$22 million gift from Alfred Taubman launches new biomedical research institute 3$22 million gift from Alfred Taubman launches new biomedical research institute 4Cardiologists and heart surgeons meet for 'Controversies and Advances' conference 2Cardiologists and heart surgeons meet for 'Controversies and Advances' conference 3
RNase-Free DNase 50 l...
DNA polymerase I, large fragment...
... Exonuclease III digests duplex DNA in ... end, 5'-overhang or nick, producing stretches of ... degradation by Exonuclease III proceeds at a ... Because the rate of exonucleolytic excision of ...
... from yeast/leuconostoc overproducer ATP: D-hexose ... 2.7.1.1/1.1.1.49. One unit of HK ... D-glucose in 1 min at ... unit of G6P-DH will oxidize ...
Biology Products: